Skip to content

A 3D Printed Human Brain Organelle Model System may contribute to the production of drugs for Neurological Disease

Share this article

LinkedInFacebookXWhatsAppE-mail

Celprogen Inc., a specialist in the Stem Cell Research and Therapeutics industry for stem research has 3D printed Brains from brain stem cells for studying neurological disease stages.

It’s been over 10 years today that the company has been working on a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants.

Thanks to the 3D printed organ, Celprogen Inc. determined 11 lead compounds, potential drug candidates for neurological diseases such as Alzheimer’s, Parkinson’s and Glioblastoma patients.

“The present invention relates to 3D organ printing programs at Celprogen that identifies potential future use in transplant of major organ systems. At present, Celprogen is validating the 3D human printed heart, pancreas, liver, hair follicle and brain for toxicology and drug discovery research.”

For further information about 3D Printing, follow us on our social networks and subscribe to our newsletter

Would you like to subscribe to 3D Adept Mag? Would you like to be featured in the next issue of our digital magazine? Send us an email at contact@3dadept.com

THE 3D ADEPT WEEKLY NEWSLETTER

The industry moves fast. Stay ahead.

Every week, the latest additive manufacturing news, in-depth features and real-world applications, straight to your inbox. Plus, be the first to know when a new issue of 3D ADEPT Mag is out.

Free · One email a week · Unsubscribe anytime

Clicking loads our email provider’s sign-up form, including its analytics and Google’s anti-bot protection. You’re only subscribed if you complete the sign-up. Read our privacy policy.

Open the form in a new tab ↗

Share this article

LinkedInFacebookXWhatsAppE-mail

The weekly newsletter

Essential AM knowledge, delivered weekly.

News, in-depth features and industry perspectives, in your inbox.

Receive the newsletter